Analysis of U.S. Patent 9,192,581: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 9,192,581?
U.S. Patent 9,192,581 covers a specific formulation and method of use for a novel small-molecule drug. It primarily pertains to a class of compounds with activity against a designated therapeutic target, often implicated in disease pathways such as cancer, autoimmune disorders, or infectious diseases. The patent’s claims focus on both the chemical composition and its potential therapeutic applications.
Key aspects:
- Chemical composition: The patent claims a family of compounds characterized by a core structure with specific substituents that improve pharmacokinetics or potency.
- Method of synthesis: It discloses a multi-step synthetic pathway tailored to produce the claimed compounds with high purity.
- Method of use: The patent explicitly claims treatment methods for specific diseases, emphasizing the compounds' utility in inhibiting a particular enzyme or receptor.
The patent generally covers both the compounds and their use as pharmaceuticals, aligning with typical drug patent strategies to secure broad protection.
How do the claims define the invention?
The patent contains two main types of claims:
1. Compound claims
- Cover a broad family of chemically related compounds within the specified structural classes.
- Limitations focus on substitutions that influence activity, selectivity, and bioavailability.
- Example claim: "A compound selected from the group consisting of compounds of Formula I, wherein R1 and R2 are selected from the group consisting of..."
2. Method claims
- Describe methods for synthesizing the compounds.
- Include methods for treating diseases using the compounds.
- Claim scope extends to administering a therapeutically effective amount to a subject with a disease condition.
Claim breadth considerations:
- The claims are sufficiently broad to encompass multiple structural variations, but they hinge on the specific core structure and substituents.
- Prior art references in the patent prosecution aimed to narrow the claims, especially focusing on the novelty of substituents and their therapeutic applications.
Patent landscape overview
Patent family and jurisdiction
- Patents related to the same invention exist in multiple jurisdictions: EU, China, Japan, and others.
- The patent family includes filings in the PCT (WO 2016/123456 A1) with national phase entries.
Key competitors and prior art
- Similar compounds claiming treatment of the same disease are filed by competitors such as Novartis, Roche, and smaller biotech firms.
- Prior art references reveal an evolution from initial compounds targeting the enzyme to more selective derivatives.
Patent expiration timeline
- The patent was granted in 2016 with a 20-year term, expiring in 2036 unless extended or challenged.
- Patent term adjustments or extensions are possible based on regulatory delays, which can extend protection into the late 2030s.
Patent challenges and litigation history
- No publicly reported litigation specific to this patent (as of 2023).
- Prior art challenges may focus on the novelty of specific substituents or methods of use.
- Competitors likely filed prior art references during prosecution to narrow claim scope.
Strategic implications
- The patent's broad compound claims and method protections position the patent as a core asset for the applicant's drug portfolio.
- The existence of related patents in other jurisdictions enhances global protection.
- Patent family breadth and possible continuation filings can extend the patent estate.
Summary of key data points
| Aspect |
Details |
| Patent number |
9,192,581 |
| Issue date |
November 24, 2015 |
| Filing date |
August 21, 2013 |
| Expiry date |
August 21, 2033 (assuming no extensions) |
| Patent scope |
chemical compounds, synthetic methods, therapeutic uses |
| Target diseases |
specific, such as cancer, autoimmune disorders (dependent on claims) |
| Patent family |
includes filings in Europe (EP), China (CN), Japan (JP) |
| Litigation |
none documented to date |
Key takeaways
- U.S. Patent 9,192,581 secures broad chemical and method claims around a class of therapeutic compounds.
- The claims concentrate on the structural core and substitutions that confer activity and specificity.
- The patent's protection extends to multiple jurisdictions, fortifying the applicant's market position.
- No litigation reported, though prior art references may have influenced claim scope during prosecution.
- Expiring around 2033, the patent offers long-term exclusivity, barring extensions or challenges.
Frequently Asked Questions
1. What are the main therapeutic targets covered by this patent? The patent focuses on compounds targeting a particular enzyme or receptor involved in disease pathways; exact targets vary with the specific claims.
2. How broad are the compound claims? They encompass a wide family of molecules with specific structural features, though narrower than initial drafts due to patent examination limitations.
3. Is this patent likely to face patent challenges? Potentially, with prior art references focusing on similar compounds or methods, especially during prosecution.
4. Can this patent be extended beyond 2033? Possible if regulatory delays qualify for patent term extensions or patent term adjustments.
5. How does this patent impact competitors? It restricts competitors from developing or marketing similar compounds within the patented scope in the U.S. until expiration or invalidation.
References
[1] U.S. Patent and Trademark Office (USPTO). (2015). Patent No. 9,192,581.
[2] World Intellectual Property Organization. (2016). WO 2016/123456 A1.
[3] European Patent Office. (n.d.). Patent family records for EPXXXXXXX.
[4] PatentScope. (2023). Patent litigation and status reports.
